Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 29, 2011, covering events occurring on June 28, 2011. The filing addresses the formal designation of a prior Sponsored Research Agreement as a material definitive agreement and the commencement of legal proceedings involving the Company.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figures disclosed relate to potential future obligations under a research agreement:
- Milestone Payments: Up to an aggregate of $1.325 million per Licensed Product directed to a particular Target.
- Royalties: Single-digit royalty payments on annual product sales.
Material Changes and Agreements
The Company reported the following material developments:
- Research Agreement Extension: Alnylam exercised its right to extend a Sponsored Research Agreement with The University of British Columbia (UBC) and AlCana Technologies, Inc. for a third year, through July 2012. The agreement focuses on discovering novel lipids for lipid nanoparticle (LNP) formulations for RNAi therapeutics.
- Intellectual Property Rights: Alnylam retains exclusive rights to new inventions regarding oligonucleotide delivery and sole rights to sublicense resulting IP. A Supplemental Agreement with Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics Inc. clarifies that Tekmira/Protiva may use these inventions for their own programs but must pay milestones and royalties to UBC and AlCana.
- Employee Waivers: Tekmira and Protiva waived restrictions on former employees now working at UBC and AlCana and granted a covenant not to sue regarding activities arising from their former employment.
Legal Proceedings and Risks
On June 28, 2011, the Company served and filed an Answer and Counterclaim in response to a lawsuit filed by Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics, Inc. The action is pending in the Business Litigation Section of the Suffolk County Superior Court in Boston, Massachusetts. The filing incorporates the Company's Answer and Counterclaim as Exhibit 99.1.
Investor Verification Checklist
- Review the full text of the Answer and Counterclaim (Exhibit 99.1) to understand the specific legal claims and counterclaims against Tekmira and Protiva.
- Verify the status of the litigation in the Suffolk County Superior Court to assess potential timelines and outcomes.
- Confirm the specific definitions of "Licensed Product" and "Target" within the Research Agreement to understand the scope of the $1.325 million milestone payments.
- Monitor future filings for updates on the collaborative research progress with UBC and AlCana through the July 2012 extension period.